CAMP4 Charts A Different Course In RNA-Based Therapeutics
Financing Snapshot: The company announced a $100m series B round that it plans to use to develop its regulatory RNA platform technology, with an eye toward entering the clinic in mid-2023.
Financing Snapshot: The company announced a $100m series B round that it plans to use to develop its regulatory RNA platform technology, with an eye toward entering the clinic in mid-2023.